Subcutaneously Administered ANTI-IL-6 Receptor Antibody for Treatment of Systemic Sclerosis

Hoffmann-La Roche Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 13/290,366, filed Nov 7, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 11,622,969	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha In force Term ends Nov 7, 2031 · Medium confidence	Chugai Seiyaku Kabushiki Kaisha	In force	Term ends Nov 7, 2031	Term ends Nov 7, 2031	Medium confidence
US 11,667,720	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha In force Term ends Nov 7, 2031 · High confidence	Chugai Seiyaku Kabushiki Kaisha	In force	Term ends Nov 7, 2031	Term ends Nov 7, 2031	High confidence
US 10,231,981	Subcutaneously Administered ANTI-IL-6 Receptor Antibody for Treatment of Juvenile Idiopathic Arthritis Chugai Seiyaku Kabushiki Kaisha In force Term ends Dec 3, 2031 · High confidence	Chugai Seiyaku Kabushiki Kaisha	In force	Term ends Dec 3, 2031	Term ends Dec 3, 2031	High confidence
US 10,874,677	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha In force Term ends Mar 2, 2032 · High confidence	Chugai Seiyaku Kabushiki Kaisha	In force	Term ends Mar 2, 2032	Term ends Mar 2, 2032	High confidence
US 9,539,263	Subcutaneously Administered ANTI-IL-6 Receptor Antibody for Treatment of Systemic Sclerosis Chugai Seiyaku Kabushiki Kaisha In force Term ends May 23, 2032 · High confidence	Chugai Seiyaku Kabushiki Kaisha	In force	Term ends May 23, 2032	Term ends May 23, 2032	High confidence
US 9,750,752	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha In force Term ends Aug 30, 2032 · High confidence	Chugai Seiyaku Kabushiki Kaisha	In force	Term ends Aug 30, 2032	Term ends Aug 30, 2032	High confidence
Application 14/061,989	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha Abandoned Abandoned Jul 13, 2016	Chugai Seiyaku Kabushiki Kaisha	Abandoned	Abandoned Jul 13, 2016	not computed
Application 17/115,391	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha Abandoned Abandoned Sep 4, 2023	Chugai Seiyaku Kabushiki Kaisha	Abandoned	Abandoned Sep 4, 2023	not computed
Application 18/459,292	Subcutaneously Administered ANTI-IL-6 Receptor Antibody Chugai Seiyaku Kabushiki Kaisha Abandoned Abandoned Sep 19, 2025	Chugai Seiyaku Kabushiki Kaisha	Abandoned	Abandoned Sep 19, 2025	not computed

9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

6 of these are in force and held by Hoffmann-La Roche Inc..

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.